Neurocrine Biosciences In... (NBIX)
Neurocrine Biosciences Statistics
Share Statistics
Neurocrine Biosciences has 98.94M shares outstanding. The number of shares has increased by -0.93% in one year.
| Shares Outstanding | 98.94M |
| Shares Change (YoY) | -0.93% |
| Shares Change (QoQ) | -1.52% |
| Owned by Institutions (%) | 93.98% |
| Shares Floating | 96.05M |
| Failed to Deliver (FTD) Shares | 312 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
The latest short interest is 3.79M, so 3.8% of the outstanding shares have been sold short.
| Short Interest | 3.79M |
| Short % of Shares Out | 3.8% |
| Short % of Float | 4.45% |
| Short Ratio (days to cover) | 3.44 |
Valuation Ratios
The PE ratio is 40.15 and the forward PE ratio is 16.35. Neurocrine Biosciences's PEG ratio is 1.22.
| PE Ratio | 40.15 |
| Forward PE | 16.35 |
| PS Ratio | 5.82 |
| Forward PS | 2.4 |
| PB Ratio | 5.29 |
| P/FCF Ratio | 24.6 |
| PEG Ratio | 1.22 |
Enterprise Valuation
Neurocrine Biosciences has an Enterprise Value (EV) of 13.93B.
| EV / Sales | 5.91 |
| EV / EBITDA | 22.83 |
| EV / EBIT | 23.39 |
| EV / FCF | 24.99 |
Financial Position
The company has a current ratio of 3.4, with a Debt / Equity ratio of 0.18.
| Current Ratio | 3.4 |
| Quick Ratio | 3.28 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | 0.75 |
| Debt / FCF | 0.82 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 13.18% and Return on Invested Capital is 12.48%.
| Return on Equity | 13.18% |
| Return on Assets | 9.18% |
| Return on Invested Capital | 12.48% |
| Revenue Per Employee | $1.31M |
| Profits Per Employee | $189.61K |
| Employee Count | 1,800 |
| Asset Turnover | 0.63 |
| Inventory Turnover | 0.59 |
Taxes
| Income Tax | 144.7M |
| Effective Tax Rate | 29.77% |
Stock Price Statistics
The stock price has increased by -23.52% in the last 52 weeks. The beta is 0.33, so Neurocrine Biosciences's price volatility has been higher than the market average.
| Beta | 0.33 |
| 52-Week Price Change | -23.52% |
| 50-Day Moving Average | 110.55 |
| 200-Day Moving Average | 127.07 |
| Relative Strength Index (RSI) | 46.65 |
| Average Volume (20 Days) | 1.51M |
Income Statement
In the last 12 months, Neurocrine Biosciences had revenue of 2.36B and earned 341.3M in profits. Earnings per share was 3.4.
| Revenue | 2.36B |
| Gross Profit | 2.32B |
| Operating Income | 570.5M |
| Net Income | 341.3M |
| EBITDA | 610.1M |
| EBIT | 583M |
| Earnings Per Share (EPS) | 3.4 |
Balance Sheet
The company has 233M in cash and 455.1M in debt, giving a net cash position of -222.1M.
| Cash & Cash Equivalents | 233M |
| Total Debt | 455.1M |
| Net Cash | -222.1M |
| Retained Earnings | 29.2M |
| Total Assets | 3.72B |
| Working Capital | 1.22B |
Cash Flow
In the last 12 months, operating cash flow was 595.4M and capital expenditures -38.2M, giving a free cash flow of 557.2M.
| Operating Cash Flow | 595.4M |
| Capital Expenditures | -38.2M |
| Free Cash Flow | 557.2M |
| FCF Per Share | 5.55 |
Margins
Gross margin is 98.56%, with operating and profit margins of 24.22% and 14.49%.
| Gross Margin | 98.56% |
| Operating Margin | 24.22% |
| Pretax Margin | 20.63% |
| Profit Margin | 14.49% |
| EBITDA Margin | 25.9% |
| EBIT Margin | 24.22% |
| FCF Margin | 23.66% |
Dividends & Yields
NBIX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 2.49% |
| FCF Yield | 4.07% |
Analyst Forecast
The average price target for NBIX is $163, which is 60.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $163 |
| Price Target Difference | 60.8% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
Scores
| Altman Z-Score | 6.55 |
| Piotroski F-Score | 6 |